A PET/CT Study to Assess the Receptor Occupancy by SAR425899 After Repeat Dosing Using Radiolabelled Tracers for the Glucagon and GLP-1 Receptor in Overweight to Obese T2DM Patients
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2018
At a glance
- Drugs SAR 425899 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 27 Sep 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 29 Mar 2018 Planned End Date changed from 1 May 2018 to 25 Jun 2018.